Brown, Lisle/Cummings, Inc. Sangamo Therapeutics, Inc Transaction History
Brown, Lisle/Cummings, Inc.
- $307 Billion
- Q2 2024
A detailed history of Brown, Lisle/Cummings, Inc. transactions in Sangamo Therapeutics, Inc stock. As of the latest transaction made, Brown, Lisle/Cummings, Inc. holds 1,525 shares of SGMO stock, worth $1,296. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,525Holding current value
$1,296% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding SGMO
# of Institutions
133Shares Held
86.3MCall Options Held
35.9KPut Options Held
156K-
Wasatch Advisors Inc Salt Lake City, UT20.1MShares$17.1 Million0.04% of portfolio
-
Armistice Capital, LLC New York, NY14.1MShares$12 Million0.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.9MShares$10.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.7MShares$4 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA4.56MShares$3.88 Million0.01% of portfolio
About SANGAMO THERAPEUTICS, INC
- Ticker SGMO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 156,552,992
- Market Cap $133M
- Description
- Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucle...